Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer
Active, not recruiting
Medivation, Inc.
Phase 2
2015-04-16
This phase II trial studies the side effects of talazoparib when given before standard
therapy in treating patients with breast cancer that has spread to nearby healthy tissue and
has a mutation in a breast cancer, early onset (BRCA) gene. Talazoparib may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth, and may be especially
effective in patients with BRCA mutations. It is not yet known whether adding talazoparib
before standard treatment is safe in treating patients with BRCA mutated breast cancer.
Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer
Active, not recruiting
National Cancer Institute (NCI)
Phase 2
2015-04-16
This phase II trial studies the side effects of talazoparib when given before standard
therapy in treating patients with breast cancer that has spread to nearby healthy tissue and
has a mutation in a breast cancer, early onset (BRCA) gene. Talazoparib may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth, and may be especially
effective in patients with BRCA mutations. It is not yet known whether adding talazoparib
before standard treatment is safe in treating patients with BRCA mutated breast cancer.
Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer
Active, not recruiting
M.D. Anderson Cancer Center
Phase 2
2015-04-16
This phase II trial studies the side effects of talazoparib when given before standard
therapy in treating patients with breast cancer that has spread to nearby healthy tissue and
has a mutation in a breast cancer, early onset (BRCA) gene. Talazoparib may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth, and may be especially
effective in patients with BRCA mutations. It is not yet known whether adding talazoparib
before standard treatment is safe in treating patients with BRCA mutated breast cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
